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review of policy research on medical
tourism in source and destination countries
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Abstract
Medical tourism occupies different spaces within national policy frameworks depending on which side of the
transnational paradigm countries belong to, and how they seek to leverage it towards their developmental goals.
This article draws attention to this policy divide in transnational healthcare through a comparative bibliometric
review of policy research on medical tourism in select source (Canada, United States and United Kingdom) and
destination countries (Mexico, India, Thailand, Malaysia and Singapore), using a systematic search of the Web of
Science (WoS) database and review of grey literature. We assess cross-national differences in policy and policy
research on medical tourism against contextual policy landscapes and challenges, and examine the convergence
between research and policy. Our findings indicate major disparities in development agendas and national policy
concerns, both between and among source and destination countries. Further, we find that research on medical
tourism does not always address prevailing policy challenges, just as the policy discourse oftentimes neglects
relevant policy research on the subject. Based on our review, we highlight the limited application of theoretical
policy paradigms in current medical tourism research and make the case for a comparative policy research agenda
for the field.
Keywords: Medical tourism, Transnational healthcare, Policy research, Bibliometric analysis, Comparative review,
North-south divide, Research-policy gap
Background
Health systems around the world are experiencing com-
mon challenges. Long wait times, tightening eligibility
restrictions, narrowing service offerings, fiscal and hu-
man resource shortages, and changing demographic pro-
files and disease burdens have made it difficult for
governments to effectively meet the healthcare needs of
citizens. Medical tourism has emerged as one of many
solutions, made possible by transnational mobility of
information, ideas, expertise, people and capital, and
growing consumerism in healthcare. Globalization has
led to high levels of standardization of medical know-
ledge, practice protocols and technologies, allowing pa-
tients in high-income countries to obtain timely, high-
quality and affordable treatment through healthcare pro-
viders in other countries. Developing countries too have
tapped into the growing popularity of medical tourism
to develop their economies. Healthcare providers in des-
tination countries and their brokers have, for instance,
taken advantage of the internet to market their services
to international consumers [1]. Countries like India and
Thailand have intentionally linked medical care with
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tourism in their messaging, to leverage their reputations
as leisure destinations [2]. Healthcare providers in
Argentina have pitched their own distinctive brand,
through association with cultural motifs like the ‘tango’
in online advertisements [3]. The extent to which destin-
ation countries have benefited has hinged on their ability
to integrate global technologies and knowhow with
unique domestic advantages.
The use of medical tourism as a welfare and devel-
opmental strategy is nonetheless contested. Its role in
bridging health system deficiencies, improving health-
care standards and stimulating local economies has
been long recognized, but there is increasing aware-
ness in recent years of the ways in which it can bur-
den public resources and deepen health inequities,
often at the cost of marginalized populations [4–7].
Medical tourism is therefore an important action
arena for policymaking, necessitated not just by the
need to encourage the industry, but also to minimize
its socioeconomic discontents, and to address its eth-
ical and legal challenges, both in countries from
which medical tourists originate, and in those they
seek healthcare [8–10].
Despite these concerns, most countries lack explicit
strategies on deploying medical tourism towards de-
fined policy goals. Decisions on the transfer of med-
ical technologies, foreign investment in health,
immigration laws for healthcare professionals and visa
provisions for overseas patients are often negotiated
as part of international trade agreements, with little
coordination across policy subsystems, or convergence
between sectoral policies despite their obvious inter-
connectedness [11, 12]. Consider the case of India,
for example. While there have been concerted at-
tempts to attract medical tourists, simplify visa pro-
cesses, publicize domestic healthcare providers
internationally and regulate medical travel agencies,
these efforts have mostly focused on the promotional
aspects and on streamlining the tourism experience,
which while important, do not address macro policy
issues such as capacity deficits, spillover effects and
incongruities between sectoral policies [13, 14]. The
background document for India’s National Health
Policy makes no mention of medical tourism, nor
does the ensuing policy engage with issues emerging
from it, although India is a major regional hub, and
the development of its private health sector has been
greatly influenced by it [15, 16]. Likewise, the policy
on M-visas is determined by the Ministry of External
Affairs, with little input from the Ministry of Health
and Family Welfare on absorption capacity and effects
on local health systems.
Poor availability of data is another challenge [17]. A
large number of medical tourists travel on ordinary
tourist visas to avoid cumbersome bureaucratic proce-
dures, keeping a significant portion of medical tourism
activity outside the purview of policymakers who might
otherwise find such information invaluable [18]. There
are definitional variations and no standardized method
for collating data on global medical travel [19]. National
databases that serve to evaluate health policies and pro-
grams, do not typically capture information on the na-
ture and quantum of transnational transactions in
medical services. Even in Canada, which has a strong
tradition of evidence-informed policymaking, the major
databases maintained by the Canadian Institute for
Health Information (CIHI) and Statistics Canada, do not
provide information on publicly funded out-of-country
care (OOCC) sought abroad privately as medical tourists
[20]. The Canadian Longitudinal Study on Aging (CLSA)
includes a variable on international travel for leisure, but
not for healthcare – despite the fact that consumers of
medical tourism services are typically elderly. As a result,
policymakers often do not have the informational means
and empirical foundations for mapping the contours of
the industry, or for making reliable assessments of its
systemic and network effects in source and destination
countries, leading to patchy policymaking [21]. That this
issue remains at the periphery of governmental strategic
thinking and a neglected policy area despite its public
significance, is surprising.
While recent research has identified global themes
in medical tourism research [22, 23], transnational
differences in policy and policy research on this sub-
ject have been less explored. Medical tourism occu-
pies different spaces within the national policy
landscapes of countries, depending on which side of
the transnational paradigm they belong to, and how
they seek to leverage it towards their goals. In this
article, we draw attention to this policy divide
through a comparative review of policy research on
medical tourism in select source (Canada, United
States [US] and United Kingdom [UK]) and destin-
ation countries (Mexico, India, Thailand, Malaysia
and Singapore). These countries are among the major
hubs of medical tourism activity and the focus of sig-
nificant empirical research in the field in recent years.
We identify themes that scholars have sought to ad-
dress, and their relative prominence in policy-related
research on these countries. Based on our review, we
assess cross-national differences in policy and policy
research on medical tourism against contextual policy
landscapes and challenges, and identify research-
policy gaps.
Methods
The review was conducted using the PRISMA (Preferred
reporting Items for Systematic review and Meta-
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Analyses) process flow developed by Moher, Liberati
et al. [24] (Fig. 1). A Boolean search of the Web of
Science (WoS) Core Collection was performed be-
tween October and November 2018 to sequentially
identify policy-related publications on medical tourism
in the selected countries for all years till date. The
search was limited to the WoS database due to the
technical challenges of multi-source comparative ana-
lyses and to facilitate more in-depth analysis of the
materials identified. We covered both open access
and subscription based publications. We included
journal articles, reviews, books, book chapters,
conference proceedings, editorial material, trade publi-
cations and industry reports, but excluded reprints,
book reviews, news articles, letters, meeting abstracts,
short surveys, conference reviews, errata, bibliograph-
ies and notes. No language or geographical restric-
tions were applied to search results.
The initial search identified publications on medical
tourism (step 1). The search was then repeated to isolate
the subset of publications on policy (step 2). A final
search was conducted to shortlist publications specific-
ally referencing select source (Canada, US and UK) and
destination countries (Mexico, India, Thailand, Malaysia
Fig. 1 Steps in the review process
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and Singapore) (step 3).1 Records were screened for du-
plicity and relevance, and those found not relevant were
removed following each search iteration. Relevance was
assessed qualitatively through a review of publication ti-
tles and abstracts (or full texts when these were either
ambiguous or insufficient) based on three criteria –
whether the materials explicitly dealt with medical tour-
ism, whether they (directly or indirectly) addressed
policy-related aspects, and whether they were rooted in
the contexts of the selected countries or contributed to
their understanding. Publications that met all the three
criteria were included in the final shortlist. Those only
tangentially alluding to but not substantively engaging
with them were excluded. The studies included in the
bibliometric review based on appraisal of the context
country, study objectives and main conclusions are out-
lined in Additional file 1 uploaded as electronic supple-
mentary material. The bibliographic data was imported
into a data visualizing software called VOSviewer to cre-
ate and visualize a network map of research themes
covered.
In addition, we searched Google and Google Scholar
search engines, and database archives such as the Public
Affairs Information Service (PAIS) Index, PolicyArchive,
IssueLab and Factiva for grey literature on policy issues
related to medical tourism in the selected countries (step
4). These included government agency reports, position
papers, industry publications, thinktank analyses and
news articles. Results from this last step (not shown in
Fig. 1) were not included in the bibliometric review, but
were rather used to supplement our interpretation of
different problem and policy contexts, and juxtapose the
identified policy research against them.
Comparative country cases
Out of the 1224 publications focused on medical tour-
ism, 62 publications explicitly address policy with
reference to one or more of the 8 selected countries
(Canada, US, UK, Mexico, India, Thailand, Malaysia and
Singapore). Figure 2 maps the key themes that scholars
have sought to address, and their relative prominence in
research with respect to each country. Table 1 juxta-
poses this research against the key policy challenges that
source and destination countries are faced with. Based
on our review, we identify cross-national patterns in pol-
icy research, and highlight synergies and gaps in research
and policy.
Source countries
Canada
Universal coverage under the Canada Health Act (CHA)
excludes certain services and classes of treatment, which
have to be sought in the private market. Moreover, the
health system is burdened with manpower shortages and
long wait times for elective procedures. Consequently,
over a million Canadians waited for treatment in 2018,
forcing many to venture abroad at personal cost to ac-
cess required healthcare [25, 26]. Concerns have been
raised regarding the safety and quality of treatment in
the private sector, both in Canada and in destination
countries, and the regulation of intermediaries that fa-
cilitate such travel and treatment [27]. Comparatively,
inbound flows are restricted due to limited private sector
offerings, and opposition to Canada’s provincial hospitals
catering to medical tourists due to implications for pref-
erential access by Canadian residents under the publicly
funded single-payer system [28].
The peculiar characteristics of the Canadian health
system have been recognized as driving these distinctive
patterns in transnational health seeking practices [29].
Yet, empirical research on their systemic drivers and ef-
fects is scarce. The objectives of most research are ex-
ploratory or descriptive, and focused on ethical and
medico-legal issues arising from outbound medical tour-
ism [30–34], contradictions between intent and policy
[35, 36], and operational challenges [37–39]. This points
to the relative nascency of policy research on Canadian
medical tourism.
United States
The American health system suffers from major gaps in
coverage, high costs of treatment, and disparities in ac-
cess and health outcomes [40]. Many Americans travel
overseas in pursuit of more affordable treatment, while
wealthy clients from across the world flock to American
hospitals to avail cutting-edge or experimental therapies.
The private sector caters not only to foreign medical
tourists, but also to domestic travellers [41]. It also facili-
tates international medical travel through accreditation
and insurance services, travel intermediation and broker-
age [21]. Medical tourism in the US has global
1We employed the following search string in step 1 to identify
publications referring to medical tourism in their titles, abstracts or
keywords: “medical tour*” OR “health tour*” OR “healthcare tour*” OR
“surgical tour*” OR “transplant tour*” OR “cosmetic tour*” OR
“reproductive tour*” OR “abortion tour*” OR “wellness tour*” OR
“medical travel” OR “health travel” OR “healthcare travel” OR “surgical
travel” OR “cosmetic travel” OR “reproductive travel” OR “wellness
travel”. Policy-related materials were demarcated in step 2 with the fol-
lowing search: (“medical tour*” OR “health tour*” OR “healthcare
tour*” OR “surgical tour*” OR “transplant tour*” OR “cosmetic tour*”
OR “reproductive tour*” OR “abortion tour*” OR “wellness tour*” OR
“medical travel” OR “health travel” OR “healthcare travel” OR “surgical
travel” OR “cosmetic travel” OR “reproductive travel” OR “wellness
travel”) AND (“policy” OR “policies” OR “regulat*” OR “governance”
OR “reform”). The syntax from step 2 was used in conjunction with
the following search terms: “Canad*” OR “U.K.” OR “United Kingdom”
OR “Brit*” OR “England” OR “U.S.” OR “United States” OR “America”
OR “India” OR “Thai*” OR “Malay*” OR “Singapore” OR “Mexic*” to
identify country-specific policy research in step 3.
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commercial tributaries and revenue streams that entails
exclusive networks and selective contracting with
overseas low-cost providers, to foster competition on
price and control costs [42, 43]. In areas like experimen-
tal therapies and biomedical innovation, cross-
jurisdictional differences in regulatory regimes, and
supply-side hegemonic networks of the medical industry,
big pharma and the government, make it easier for sup-
pliers to skirt stringent regulation and render demand-
led consumer-driven governance approaches ineffective,
unless accompanied by domestic advocacy, or policy ini-
tiatives in destination countries to trigger conformity by
western suppliers [44–46].
Such analytical nuance and the range of practical solu-
tions that have been devised can be attributed to the in-
dustry being better researched, and policy research being
more evolved and contextually oriented to regional real-
ities in the US, than for instance, in Canada. Researchers
have studied how factors such as transnational regula-
tions, international treaties and trade agreements [47,
48], domestic healthcare reforms [49], structural dispar-
ities [29, 50, 51], market forces [29, 50], personal prefer-
ences of medical tourists [52, 53] and destination
country characteristics [53, 54] affect cross-border
healthcare. It has been argued that the focus on cost sav-
ings in policy debates in the US neglects such concerns
as access, equity, quality and capacity, which occupy the
centre stage in policy thinking in countries like Canada
and the European Union [29, 55]. Researchers have, for
instance, highlighted how regulatory approaches in the
US tend to disregard, and sometimes aggravate concerns
about patient protection, patient choice, and ethically
questionable technologies [56, 57], but selectively adopt
a moral high ground or leave regulatory ambiguity when
convenient [58, 59].
United Kingdom
Some of UK’s issues are similar to Canada’s. Cutbacks in
National Health Service (NHS) funding, shortage of
healthcare professionals, long wait times, treatment time
Fig. 2 Co-occurrence network of keywords in policy-related publications on medical tourism in select source and destination countries. The
figure shows the relatedness of author designated and auto indexed keywords (with at least three occurrences) based on how frequently they
occur in the same publications. Nodes depict keywords and their linkages convey co-occurrence relationships. Larger nodes indicate keywords
with more occurrences. Link strengths indicate the frequency with which they co-occur. Keywords that co-occur more frequently are clustered
together in nodes of the same color
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Table 1 Policy challenges of medical tourism in source and destination countries and issues addressed in policy research
Country Key policy challenges Issues addressed in policy research
Canada Patient wait times
Physician shortages
Quality of care in private sector
Effectiveness and safety of stem cell therapies
Regulation of medical tourism companies
Effects on provincial healthcare systems
Access to private healthcare for residents
Standards of care in destination countries
Institutional drivers of medical tourism
Patterns of medical tourism and effects on preferential access
Development of health and safety advisory for caregiver-companions
Ethical and legal concerns of medical tourism
Obligations of healthcare providers towards outbound patients
Facilitation of medical tourism
Physician concerns with care quality and continuity
US High healthcare costs
Cost-control challenges and moral hazard
Disparities in access
Selective coverage
Effectiveness and safety of experimental therapies
Regulation of medical and pharmaceutical industries
Standards of care in destination countries
Institutional drivers of medical tourism
Motivations for medical travel
Transnational differences in policy goals
Regulatory barriers
Domestic medical tourism
Legal protections for medical tourists
Market for selective technologies and its ethical concerns
Ethical and logistic challenges of transplant tourism
Transparency in organ transplantation
UK NHS cutbacks
Shortage of healthcare professionals
Immigration rules for healthcare professionals
Patient wait times
High cost of private healthcare
Effects of treatment time guarantee
Ethics of private sector contracting
Access to medicinal cannabis
Rights of UK citizens to healthcare in the EU
Cross-border jurisdiction issues
Healthcare coverage for migrants and visitors
Revenue generation from medical tourism
Effectiveness, safety and legality of experimental
therapies
Standards of care in destination countries
Insurance protection for outbound medical tourists
Spread of drug-resistant superbugs
Effects of Brexit
Estimates of medical tourism flows
Economic and health system implications
Motivations for medical travel
Rights and entitlements of migrants and visitors
Access to abortion services and barriers to legal reform
Regulation of international surrogacy, stem cell markets and organ trafficking
Bilateral agreements in medical tourism
Mexico Market for medical tourism and its economic potential
Supply-side capacities and constraints
Mexico’s role in global public health
Medical risks and safety concerns
Use of Mexican medical providers by US patients, insurers and hospitals
Cross-border health seeking by US Hispanic immigrants
Supply-side drivers and impediments
Effects of economic integration
Binational insurance
Effects of healthcare reforms on cross-border healthcare
Regulation of stem cell treatment
India Market for medical tourism and its economic potential
Government’s role in promoting medical tourism
Distortionary effects on health system and equity
implications
Motivations for medical travel and patient experiences
Medical tourism development
Impact on health system and health workforce
Ethical concerns and gaps in regulation of assisted reproduction, organ
transplantation and stem cell treatment
Bilateral agreements in medical tourism
Thailand Market for medical tourism and its economic
potential
Competitiveness
Government’s role in promoting medical
tourism
Distortionary effects on health system and equity
implications
Perceptions of medical tourists and implications for destination choice
Patient experiences
Medical tourism development
Economic and health system implications
Regulation of assisted reproduction and its limitations
Malaysia Market for medical tourism and its economic
potential
Competitiveness
Government’s role in promoting medical
tourism
Distortionary effects on health system and equity
implications
Perceptions of medical tourists and implications for destination choice
Motivations for medical travel and care seeking behavior
Medical tourism development
Competitiveness
Economic and health system implications
Ethical and legal concerns
Sustainable development
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guarantees, drug controls and the high cost of private
healthcare, drive thousands of patients to healthcare des-
tinations in Eastern Europe and Asia every year. Hane-
feld and Horsfall [60] and Lunt, Smith et al. [61] have
examined some of these motivations for travel abroad.
Private sector contracting has sought to relieve pressure
on the public healthcare system, but raised ethical and
equity concerns. The UK has had to additionally con-
tend with regulatory differences among its constituent
countries, and challenges arising from EU membership,
such as the rights of UK citizens in the EU, questions of
extraterritorial application of domestic laws and trans-
regulatory disparities. For example, researchers have
drawn attention to legal barriers in accessing abortion
services in Northern Ireland [62], weaknesses in the
regulation of international surrogacy [63], regulatory de-
ficiencies which allow circumvention of statutory restric-
tions on organ trafficking [64], lack of conceptual
harmonization in the regulation of stem cell innovation
[45] and implementation overreach in NHS practices to-
wards EU visitors [65].
In addition, UK’s experience with medical tourism has
drawn attention to common concerns about the effect-
iveness, safety and legality of experimental therapies, and
standards of care in destination countries. Internally, it
has highlighted gaps in insurance protection for out-
bound medical tourists, public health challenges arising
from cross-border spread of antibiotic-resistant superb-
ugs, and the inadequacy of data on international medical
travel. There have been calls for moving towards re-
gional or bilateral frameworks to redress such issues, but
political considerations and electoral expediency have
posed challenges [66].
Public debates have been shaped by political rhetoric
largely centred on immigration, access to free healthcare
for migrants and visitors, and the role of the NHS. While
there is little evidence that this compromised the care of
vulnerable populations, it has created confusion and un-
certainty among care providers and consumers [67].
Many assumptions driving policy on these issues have
been contested by recent research. For example, data on
cross-border flows shows that medical tourism accounts
for only a fraction of the NHS health spending, and that
concerns about it burdening taxpayers are misplaced
and overstated. To the contrary, it is a significant
contributor of revenue. Moreover, the UK is a net ex-
porter of medical tourism, and by implication a social
beneficiary of cross-border healthcare [68]. In the wake
of the uncertainty surrounding Brexit, there are ques-
tions about how medical tourism and future coordin-
ation with EU members on healthcare might be affected.
There has been conjecture about possible scenarios, but
no externally facing analysis or investigation of its likely
effects and implications is available.
Destination countries
Mexico
Mexico is the world’s second largest medical tourism
market, after Thailand, and annually attracts over a mil-
lion medical tourists, particularly from the US and
Canada. The focus of both federal and regional govern-
ments has been on policies to promote Mexican prov-
inces as destinations for low-cost medical tourism, and
developing medical, hospitality and recreational infra-
structure to cater to inbound flows. These include train-
ing of healthcare professionals with bilingual language
proficiency, increasing the number of accredited private
hospitals, collaborating with overseas insurers and
healthcare providers to establish referral and feeder net-
works, and creating medical clusters to tap unused cap-
acities in existing private hospitals to service foreign
clients.
While these initiatives have helped, structural barriers
such as high market entry costs, visa restrictions and
poor portability of health insurance have impeded sector
development [69]. US Hispanic immigrants constitute a
major segment of medical tourists in Mexico, partly due
to care perceptions and personal preferences, but also
due to the difficulties in obtaining required healthcare in
the US [51, 70]. Researchers have suggested how cross-
border insurance plans, immigration and healthcare re-
forms, and regional economic integration and trade
agreements can remove some of these barriers, expand
healthcare coverage and address regulatory grey zones
[48–50].
India
India ranks fifth on the global Medical Tourism Index,
second in Asia. Its private sector has made huge invest-
ments in hospital infrastructure, high-end medical
Table 1 Policy challenges of medical tourism in source and destination countries and issues addressed in policy research
(Continued)
Country Key policy challenges Issues addressed in policy research
Adaptation in organ donation legislation and transplant policy
Singapore Patient satisfaction
Competitiveness
Medical tourism development
Competitiveness
Economic and health system implications
Adaptation in organ donation legislation and transplant policy
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technologies, network logistics and supply chains, to
make state-of-the-art healthcare available to foreign cli-
ents at low cost [71]. The government has aided devel-
opment through policies incentivising the private sector
and clearing regulatory hurdles. This includes promo-
tional campaigns, simplification of visa rules, financial
support to medical tourism providers, registry for accre-
dited agents to discourage touting, and a National Med-
ical and Wellness Tourism Board (NMWTB) to
formulate policy and guidelines for the sector. Debata,
Sree et al. [72] have identified the key enablers of med-
ical tourism in India and their effects.
However, there has been little interest among policy-
makers in regulating private healthcare providers to
manage quality and safety concerns, or addressing staff
shortages and resource pressures in the public sector
due to the insidious transfer of human resources and
state subsidies to the private sector through both diffu-
sionary and policy-led mechanisms [21, 73–77]. In areas
where attempts to regulate have occurred, as in the case
of assisted reproductive technologies, organ transplant-
ation and stem cell research, regulatory instruments
have been found to be inadequate, ambiguous, and
oftentimes contradictory [46, 78–83]. Such weaknesses
in regulatory frameworks and domestic political con-
straints have hampered regional and bilateral cooper-
ation in the sector [66].
Thailand
Thailand is the world’s top medical tourism destination
and a major regional hub for patients from East and
South-East Asia, competing with Japan, South Korea and
Malaysia for regional dominance. High clinical standards
and service quality at low cost, combined with extensive
tourism infrastructure and leisure options, have created
a strong preference for Thailand among medical travel-
lers [84–86]. Medical tourism is part of the core busi-
ness model of Thai private hospitals. Moreover,
Thailand is regionally unique, in that it has a compre-
hensive health system architecture with high govern-
ment investment in medical education and public
health, a tightly regulated healthcare environment and
universal health coverage [87]. Medical tourism is
viewed by policymakers as a means to leverage the
strengths of the health system to offset the budget bur-
den towards social spending. The Royal Thai Govern-
ment has aided this sector by placing it high on the
policy agenda, easing visa restrictions for medical tour-
ists, granting long-stay visas for travellers from ASEAN
Plus Three countries (China, Japan and South Korea)
and via promotional campaigns. Bochaton [88] has ex-
amined these developments and highlighted some of the
key socio-political and economic drivers that have
contributed.
Nonetheless, there are concerns about the effects of
medical tourism on the health system, such as through
internal migration of healthcare professionals, burdens
created by foreign retirees seeking long-term end-of-life
care, and cost inflation for the local population [21, 87,
89–91]. A range of policy prescriptions have been of-
fered – integrated human resource planning, increased
private sector contribution to human resource develop-
ment, lifting restrictions on the recruitment of inter-
national medical graduates, levying a medical tourist tax
to transfer some of the commercial gains from medical
tourism to the health system, and reviewing policies for
long-stay tourism. The government has taken some
countermeasures, such as fee schedules for controlling
medical costs, but many of the structural issues remain
unaddressed. Besides, while bona fide regulatory efforts
in areas such as commercial surrogacy and assisted
reproduction have succeeded in clarifying legal positions
and pre-empting litigation, they have presented new eth-
ical and practical challenges, such as restrictions on
same sex couples seeking surrogacy arrangements, and
the use of human embryos for research [92].
Malaysia
Malaysia offers a clear pricing advantage as compared to
neighbouring Singapore. However, there have been ap-
prehensions that it may not enjoy a distinctive brand
recognition like its regional competitors, as it has to
compete with countries like India and the Philippines on
cost, and with others like Thailand and Singapore on
quality and consistency [93]. The Malaysian government
has implemented a slew of measures, from Green Lane
clearance to make it easier for medical travellers to seek
healthcare in Malaysian hospitals, to industry recogni-
tion awards, accreditation programmes, infrastructure
development and global promotion of brand Malaysia.
All the same, policymakers have failed to consider the
socio-economic diversity, social networks and contextual
characteristics of clients from regional markets like
Indonesia and international retiree migrants in Malaysia
in their zeal to appeal to the global medical tourist [94,
95]. Ormond and Sulianti [94] have attributed this dis-
parity to Northerner bias. Others like Manaf, Hussin
et al. [96] have suggested this may be a deliberate strat-
egy by policymakers to avoid becoming overdependent
on single source markets. Moreover, the development of
Malaysia’s medical tourism industry has been concomi-
tant with the rise of the private sector in health, and the
withdrawal of the state from its welfarist agenda [97, 98].
Policies for medical tourism have tended to focus on
maximizing indirect economic gains, while more obvious
health system implications have been neglected [87, 99].
Failure to devise policies to address such concerns has
resulted in critical regulatory gaps, producing less
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desirable and often inequitable outcomes [100–102].
The Malaysian case highlights the need for more con-
textually situated, and socially aligned policy and prac-
tice that is sensitive to, and has the support of diverse
domestic stakeholders [103, 104].
Singapore
Medical treatment in Singapore costs significantly more
as compared to other destination countries. Minimal
government oversight of tourism activity and lack of
stringent price controls in the private sector have con-
tributed to cost inflation. This combined with other inci-
dentals such as the high cost of living, makes it difficult
for Singapore to maintain its competitiveness against re-
gional rivals like Malaysia, India and Thailand, given
how aggressively these countries have worked to develop
their infrastructure and capacities, while operating at
much lower costs. As a result, Singapore’s attractiveness
as a medical tourism destination has somewhat dimin-
ished, because overseas patients have been diverted to
more competitive markets in the immediate
neighbourhood.
While the government provides only minimal direct
assistance to medical tourism providers unlike in some
other destination countries, it has supported the sector
through targeted economic and industrial policy and in-
centive regime, broad-based supply-side reforms and a
strong regulatory framework for corporate governance
and legal regulation of firms. This has helped create a
business-friendly climate, provided the required institu-
tional scaffolding to ensure sound management account-
ability and sustainable development of the sector, and
facilitated public-private collaboration and strategic co-
operation between commercial players to establish a
range of critical competencies. These include: 1) bio-
medical research and innovation labs such as the Agency
for Science, Technology and Research (A*STAR) and
SingHealth’s Investigational Medicine Unit; 2) the inter-
agency government-industry partnership known as
Singapore Medicine that coordinates national policy and
strategy on medical tourism; 3) a globally-oriented med-
ical education system with residency programs struc-
tured on American medical licensing norms,
scholarships for physicians to train overseas and global
partnerships such as the Duke–NUS Graduate Medical
School; 4) healthcare accreditation systems based on
international standards such as the Joint Commission
International (JCI) and those mandated by local accredit-
ing agencies like the Singapore Accreditation Council
(SAC), the Ministry of Health and the Health Promotion
Board (HPB); and 5) support sectors such as Meetings,
Incentives, Conventions, and Exhibitions (MICE), infor-
mation technology, and smart infrastructure [87, 93,
105, 106]. Thus, despite its cost disadvantage, Singapore
has managed to create a unique niche for itself through
purposive, policy-driven interventions that have built on
and contributed to the development of technological su-
periority, technical efficiency, service quality and a com-
prehensive services ecosystem, which have helped better
address concerns on safety and quality of care, and de-
liver superior patient experience relative to regional
competitors.2
Though public hospitals are under government owner-
ship, they are managed autonomously, and compete for
patients in the open market. This induces competition
on quality, but also provides avenues for cross-
subsidization and economies of scale [87, 98]. Unlike
Malaysia, where the public and private sectors have
grown further apart, in Singapore, they have converged
to offer relatively similar quality and scope of services,
making public hospitals equally attractive to medical
tourists. Programs and policies for medical tourism are
therefore as likely to influence the behaviour of public
hospitals, as of those in the private sector. While this
can potentially translate to efficiency gains for public
hospitals, theoretically it can also produce adverse public
outcomes and compromised care for local residents, un-
less calibrated through policy. To minimize such distor-
tions, the government has implemented stringent
administrative controls to regulate the quality of care in
public hospitals and adopted creative human resource
policies. For instance, Singapore has successfully man-
aged to attract high quality health workers from neigh-
bouring countries like India, Pakistan, Sri Lanka,
Malaysia, Myanmar and the Philippines over the years
through international recruitment efforts, offer of com-
petitive public sector salaries, and training and career
development opportunities [87]. More recently, the gov-
ernment has attempted to reverse its previous policy
position on public sector participation in medical tour-
ism and restricted public hospitals from actively market-
ing themselves via foreign agents to address critical
shortages in hospital beds and prioritize local healthcare
needs such as those of an aging population, over those
of foreign patients. While this may have realigned the in-
ternal medical tourism market in favour of private sector
operators such as Parkway Holdings and the Raffles
medical group which depend on medical tourists to feed
their revenue streams and expand their domestic foot-
print, the public mandate of public hospitals has come
to be better recognized in policy discourse, and better
protected through government action.
2Singapore was ranked top among seven Asian medical destinations in
terms of patient experience but least attractive on cost considerations
as per an index developed by AB Bernstein and Global Health and
Travel in 2017.
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A similarly pragmatic approach can be seen in Singa-
pore’s organ donation legislation and transplant policy,
where the government has attempted to draw a balance
between promoting self-sufficiency in organ supply on
the one hand, and minimizing the risk of exploitation on
the other. Amendments to the Human Organ Trans-
plant Act (HOTA) have relaxed donor eligibility norms
to allow paired matching for the exchange of organs to
increase the chances of better transplant outcomes. They
also permit compensation to living donors for direct and
indirect costs associated with organ donation through
their medical savings accounts to minimize the risk of
organ trade. The policy exhibits features of adaptive pol-
icy change geared towards addressing both the practical
and ethical challenges of transplant tourism [102, 107].
Such pragmatism, while not unique to Singapore, differ-
entiates it from other destination countries in its league,
in terms of the responsiveness, responsibility and pur-
posive intent of policymaking.
Study limitations
Our assessment of the country cases is constrained by
methodological weaknesses inherent to the design of
bibliometric studies and qualitative comparative analyses
of this kind. Some of these issues are discussed below to
help the reader better contextualize the results and our
conclusions.
Our search was limited to the WoS database, and
did not include discipline-specific databases such as
EconLit (economics), PubMed (biomedical and life
sciences) and PsycINFO (psychology and behavioural
sciences). Nonetheless, a significant proportion of
their publications are cross-indexed in WoS, and
therefore, while our search cannot be claimed as all-
inclusive, it provides us with a reasonably representa-
tive snapshot of the state of medical tourism and pol-
icy research in the selected countries. Moreover, WoS
has a significant overlap with Scopus, which is a lar-
ger database. Both tend to underrepresent the social
sciences, arts and humanities, and both favour publi-
cations in the English language, which are key limita-
tions [108].
The study uses Boolean search to identify publications
on medical tourism, filter out those that do not directly
refer to policy aspects and further shortlist those dealing
with policy specifically in the context of the selected
countries. While we employed keyword combinations
and search iterations including synonyms and truncation
or wildcard searches to get more comprehensive results,
it is but inevitable that some relevant literature may have
fallen through the cracks, while less significant works
may have been included. For instance, we used a fairly
narrow and explicit operationalization of policy research
as works referring to policy, governance, regulation or
reform. This might have caused some of the less explicit
yet policy-relevant works to be overlooked in our search.
Further, given the subjective nature of the appraisals
(steps 1a–3a), the pooled shortlist represents the
authors’ collective judgement about the relevance of
included works. Such subjectivity is likewise reflected in
the nature of comparative lesson-drawing and gap-
assessment presented in this paper. While some subject-
ivity is inevitable, we acknowledge that it affects replic-
ability. Our aim was to balance the objectivity of a
keyword-based search strategy to enhance replicability,
with the application of mind for the determination of
relevance, to improve the quality of the shortlist. More-
over, the objectives of our study are exploratory, not ex-
planatory. The paper does not seek to establish causal
connections, but rather to expose gaps in and between
research and policy. A partly subjective approach was
necessary for meaningful appraisal of the literature from
this perspective.
Lastly, the distinction between source and destination
countries in this paper is purely instrumental, as many
countries are concurrently both providers and con-
sumers of medical tourism for different services and to
different degrees. For example, patients from India rou-
tinely travel to the US to benefit from newer medical
technologies such as in stem cell and cancer research,
while American patients visit India to overcome cover-
age issues and avoid high costs of treatment in the US.
Such overlaps make the task of identifying country-
specific policy challenges more complex and render
source-destination policy comparisons muddled.
Conclusions
These limitations notwithstanding, some interesting
comparative insights are offered by the study. Firstly, we
see major differences in national policy concerns, not
only between source and destination countries, but also
among them, given their unique socio-political contexts,
developmental pressures and policy challenges. The di-
versity in policy research reflects their different realities
(Table 1). How policymakers approach issues of cross-
border healthcare, depends on which side of the trans-
national divide countries are located on, and how they
seek to leverage the potential of medical tourism for the
achievement of national policy goals.
Policymaking in destination countries is mostly di-
rected towards developing supply-side capacities and
competitiveness, without being particularly attentive to
the distortionary effects on local health systems and the
regulatory weaknesses that engender them. For instance,
the governments of Mexico, India, Thailand and
Malaysia have focused much of their policy attention,
economic resources and governance capacities on pro-
moting their provinces as destinations for low-cost
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medical tourism, incentivising private sector operators
to strengthen medical and tourism infrastructure for
medical tourists, and addressing regulatory hurdles for
investors and consumers, often neglecting the health
needs and wellbeing of their own populations, and the
safety of medical tourists.
Source country policies, on the other hand, are de-
signed to facilitate outbound medical travel to overcome
domestic health system deficiencies and assure care
standards in destination countries, while doing little to
address the discriminatory application of ethical and
regulatory norms to medical travel to those countries, or
fix the issues that drive the exodus. Policymaking in the
US, for example, has focused less on resolving the struc-
tural issues that limit healthcare access and coverage
within the US, and more on establishing cross-border in-
surance mechanisms, transnational cost-saving arrange-
ments and global networks of accredited healthcare
providers to enable travel for treatment overseas. In the
UK, a recent amendment to Northern Ireland’s abortion
law has now made abortion services universally access-
ible. At the same time, however, both Canadian and UK
laws for the regulation of transnational surrogacy and
transplant tourism remain weak and ineffective in pro-
tecting surrogate mothers and organ donors in destin-
ation countries from exploitation.
The lop-sidedness in government priorities has skewed
the narrative on medical tourism from that of a catalyst
for socioeconomic development, health sector improve-
ment and universal health coverage to a vehicle for eco-
nomic growth and healthcare outsourcing. This
divergence has created policy overlaps, tensions and fault
lines between the Global North and South. While there
is cross-national directional convergence in efforts to fa-
cilitate the travel of medical tourists, there remain crit-
ical gaps that cause treatment complications and
hamper continuity of care in source countries, disadvan-
tage vulnerable groups in destination countries, and cre-
ate health inequities between source and destination
countries. Addressing these requires the development of
a global framework for the collaborative governance and
enforcement of transnational processes of medical tour-
ism, and mechanisms for policy coordination and regula-
tory convergence between source and destination
countries to ensure policy alignment. It follows there-
from that policymakers need to explicitly consider what
they seek to achieve through medical tourism in the
context of their developmental goals, and purposively
design a policy architecture that optimizes their gains
and minimizes risks across the value chain. In source
countries, this might, for example, involve legislative
changes to facilitate extraterritorial application of pro-
tective provisions to prevent exploitation, and
rationalization of regulatory restrictions and health
system reforms to reduce the need for citizens to travel
abroad for treatment. In destination countries, it might
include cross-subsidization arrangements to transmit re-
sources internally, incentive and regulatory regimes to
control brain drain, and capacities to assure care quality
and continuity through standardized treatment proto-
cols, certification systems and networked electronic
medical record exchange. It is notable that Singapore
has been defter at navigating this divide. It has better ad-
dressed source country concerns on safety and quality of
care as compared to its peers, and at the same time
taken steps to insulate its health system from the unin-
tended consequences of medical tourism. Its inward-
focused and pragmatic policy approach may have poten-
tially contributed to shielding it from some of the same
problems that other destination countries have encoun-
tered, even as it has successfully managed to maintain its
unique market position within the region.
Second, we find that research and policy are not al-
ways congruent. There are several areas where there are
gaps from research being out of step with prevailing pol-
icy concerns. For instance, policy research in Canada is
focused on drawing attention to the ethical and medico-
legal concerns of medical tourism, and its undermining
effects on access and equity, but does not adequately ad-
dress the inherent weaknesses of the Canadian health-
care system that compel Canadians to seek treatment
overseas, or the regulatory underpinnings that give rise
to ethical conflicts. Likewise, there are areas where the
policy discourse has failed to take heed of relevant policy
research. In the UK, resistance to skilled worker immi-
gration despite the high dependence of the NHS on for-
eign medical professionals, and the narrative driving
policy against healthcare coverage for migrants despite
lack of empirical evidence on systematic abuse, is a case
in point. While it is well-recognized that policy and re-
search seldom fully converge since the political econ-
omies that shape them operate autonomously and are
slightly different, major incongruencies, like those men-
tioned above, can be mediated through better channels
for collaboration and communication between re-
searchers, policymakers and interest groups. Internation-
ally, and especially in the health sector, knowledge
platforms and policy labs are playing an increasingly im-
portant role in widening the evidence base for public
policy through analytical inputs to help governments
formulate better policy responses, building trust and
confidence among diverse stakeholders, and co-
producing research that is relevant to policymaking
needs [109, 110]. Such initiatives in the medical tourism
sector could go a long way in strengthening research-
policy linkages, addressing obvious gaps in research and
policy, and facilitating effective uptake of research by
governments. Canada, for example, has a strong
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tradition of evidence-informed policymaking, and ini-
tiatives such as the McMaster Health Forum have
contributed immensely to deliberative dialogues be-
tween health researchers, providers, managers and
policymakers to optimize the use of research evidence
in policymaking and practice [111]. These mecha-
nisms can be leveraged for greater coordination be-
tween medical tourism policy and research. Beyond
research-policy linkages, UK’s example of how polit-
ical considerations can sometimes get the better of
empirically-grounded policy advice, highlights the
need for greater technocratic control over decision-
making to the extent possible in democratic systems.
While the role of political triggers in policymaking
cannot be ignored, formal institutionalization of re-
search into policymaking processes can help better in-
sulate them from extraneous political influences and
minimize political risk.
Our final point relates to the amenability of medical
tourism research to a comparative policy perspective
(Fig. 3). Consider, for example, the processes of diffu-
sion that have helped countries supplying medical
tourism services to optimize costs, upgrade technol-
ogy, develop skills and knowhow, strengthen capacity
and raise quality standards. The contagious character
of globalization is likewise responsible for the
widespread acceptance of the western biomedical con-
cept of health, replication of clinical best practices,
research advancements in new treatments and
technologies, establishment of accreditation standards
and certification systems, adoption of quality improve-
ment methodologies by healthcare organizations, and
cross-pollination of alternative systems like Homoeop-
athy in the Asian subcontinent, and Ayurveda and
Yoga in the western world. Medical tourism has ac-
celerated such diffusionary phenomena, which have in
turn fueled its growth. In other cases however, it has
slowed or reversed existing trends such as brain-
drain, as working conditions back home have become
more attractive. Such reversals have shifted the loci of
existing policy problems and transplanted them to
other pockets of the subsystem, requiring a different
set of policy responses. For example, healthcare
workers in countries like India, Malaysia and Thailand
are increasingly migrating to the private sector to ser-
vice foreign clients, leading to human resource short-
ages in the public health system, and forcing a
rethink of domestic regulatory policies and human re-
source practices. Medical tourism has also brought to
the forefront a number of practical difficulties, ran-
ging from incompatibilities in medical norms and
payment systems, to issues of contested citizenship
and non-transferability of entitlements [8, 112–115].
Such fault lines typically arise from cross-border het-
erogeneity in policy regimes, poor regulatory coordin-
ation and lack of cooperative frameworks. Yet, there
is limited application of theoretical policy paradigms
and comparative analysis in current medical tourism
Fig. 3 The intersection of medical tourism and policy studies
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research. This article makes a plea for a comparative
policy research agenda for medical tourism that rec-
ognizes the need for holistic evaluation of its differen-
tial effects in source and destination countries,
acknowledges the diversity in national policy concerns
and priorities, and deploys appropriate policy frame-
works and theories to help discern its various
challenges.
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